Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02714218
Registration number
NCT02714218
Ethics application status
Date submitted
16/03/2016
Date registered
21/03/2016
Date last updated
24/06/2022
Titles & IDs
Public title
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Query!
Scientific title
Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination With Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination With Ipilimumab 3 mg/kg in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Query!
Secondary ID [1]
0
0
CA209-511
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Nivolumab 3 mg/kg IV
Other interventions - Ipilimumab 1 mg/kg IV
Other interventions - Nivolumab 1 mg/kg IV
Other interventions - Ipilimumab 3 mg/kg IV
Other interventions - Nivolumab 6 mg/kg IV
Experimental: Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg IV - Specified dose on specified days
Experimental: Ipilimumab 3 mg/kg IV + Nivolumab 1 mg/kg IV - Specified dose on specified days
Experimental: Nivolumab 6 mg/kg IV + Ipilimumab 1 mg/kg - Specified dose on specified days
Other interventions: Nivolumab 3 mg/kg IV
Followed by Nivolumab monotherapy
Other interventions: Ipilimumab 1 mg/kg IV
Followed by Nivolumab monotherapy
Other interventions: Nivolumab 1 mg/kg IV
Other interventions: Ipilimumab 3 mg/kg IV
Other interventions: Nivolumab 6 mg/kg IV
A dose of 240mg is identical to a dose of 3mg/kg, therefore 6mg/kg is approximately equal to ~ 480mg.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The Percentage of Participants With Drug-Related Grade 3 - 5 Adverse Events (AEs)
Query!
Assessment method [1]
0
0
The percentage of participants who experienced at least 1 AE of Grade 3 or higher, judged to be related to study drug by the investigator, and with onset on or after the first dose of study treatment and within 30 days of the last dose of study treatment. AE grade was defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria.
Query!
Timepoint [1]
0
0
From first dose of study treatment up to primary completion date 20-Apr-2017 (up to approximately 12 months)
Query!
Secondary outcome [1]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [1]
0
0
The percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). BOR is defined as the best response, as determined by the investigator, recorded between the date of randomization and the date of progression per RECIST 1.1 or the date of subsequent anticancer therapy, whichever occurred first. For subjects without documented progression or subsequent therapy, all available response designations will contribute to the BOR assessment. Tumor assessments are scheduled at Week 12 following randomization, every 8 weeks for the first 12 months and then every 12 weeks until disease progression. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Query!
Timepoint [1]
0
0
From date of randomization to date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to approximately 5 years)
Query!
Secondary outcome [2]
0
0
Overall Survival (OS)
Query!
Assessment method [2]
0
0
The time between the date of randomization and the date of death due to any cause. A participant who has not died will be censored at the last known alive date. OS will be followed continuously while participants are on the study drug and every 3 months via in-person or phone contact after participants discontinue the study drug. Based on Kaplan-Meier Estimates.
Query!
Timepoint [2]
0
0
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first (up tp approximately 5 years)
Query!
Secondary outcome [3]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [3]
0
0
The time between the date of randomization and the first date of documented progression, determined by the investigator, or death due to any cause, whichever occurs first. Participants who die without a reported progression will be considered to have progressed on the date of their death. Those who did not progress or die will be censored on the date of their last evaluable tumor assessment. Participants without on study tumor assessments and who did not die will be censored on their date of randomization. Participants who started anti-cancer therapy without a prior reported progression will be censored on the date of their last evaluable tumor assessment prior to the initiation of subsequent anti-cancer therapy. Based on Kaplan-Meier Estimates. Progression is defined as at least a 20% increase in the sum of diameters of target lesions. The sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
Query!
Timepoint [3]
0
0
From randomization to the first date of documented progression or death due to any cause, whichever occurs first (up to approximately 5 years)
Query!
Secondary outcome [4]
0
0
Mean Changes From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Physical Functioning Scale
Query!
Assessment method [4]
0
0
Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. The Physical Functioning Scale sub-scale item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores indicate a higher level of symptoms; lower scores indicating lesser burden and improved symptoms or quality of life. A clinically meaningful change in score may be regarded as 10 points.
Query!
Timepoint [4]
0
0
Weeks 7, 16, 20, 24, 28, 32, 36, 40
Query!
Secondary outcome [5]
0
0
Mean Changes From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Role Functioning Scale
Query!
Assessment method [5]
0
0
Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. The Role Functioning Scale sub-scale item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores indicate a higher level of symptoms; lower scores indicating lesser burden and improved symptoms or quality of life. A clinically meaningful change in score may be regarded as 10 points.
Query!
Timepoint [5]
0
0
Weeks 7, 16, 20, 24, 28, 32, 36, 40
Query!
Secondary outcome [6]
0
0
Mean Changes From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Emotional Functioning Scale
Query!
Assessment method [6]
0
0
Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. The Emotional Functioning Scale sub-scale item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores indicate a higher level of symptoms; lower scores indicating lesser burden and improved symptoms or quality of life. A clinically meaningful change in score may be regarded as 10 points.
Query!
Timepoint [6]
0
0
Weeks 7, 16, 20, 24, 28, 32, 36, 40
Query!
Secondary outcome [7]
0
0
Mean Changes From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Cognitive Functioning Scale
Query!
Assessment method [7]
0
0
Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. The Cognitive Functioning Scale sub-scale item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores indicate a higher level of symptoms; lower scores indicating lesser burden and improved symptoms or quality of life. A clinically meaningful change in score may be regarded as 10 points.
Query!
Timepoint [7]
0
0
Weeks 7, 16, 20, 24, 28, 32, 36, 40
Query!
Secondary outcome [8]
0
0
Mean Changes From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Social Functioning Scale
Query!
Assessment method [8]
0
0
Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. The Social Functioning Scale sub-scale item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores indicate a higher level of symptoms; lower scores indicating lesser burden and improved symptoms or quality of life. A clinically meaningful change in score may be regarded as 10 points.
Query!
Timepoint [8]
0
0
Weeks 7, 16, 20, 24, 28, 32, 36, 40
Query!
Secondary outcome [9]
0
0
Mean Changes From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Global Health Status
Query!
Assessment method [9]
0
0
Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. The EORTC QLQ-C30 comprises 6 functional scales (role function, physical functioning, cognitive functioning, emotional functioning, social functioning and global quality of life) as well as nine symptom scales (fatigue, pain, nausea/vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). With the exception of 2 items included in the global health/quality of life scale, for which responses range from 1 (Very poor) to 7 (Excellent), item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores for all functional scales and Global Health Status indicate better HRQoL; an increase from baseline indicates improvement in HRQoL compared to baseline.
Query!
Timepoint [9]
0
0
Weeks 7, 16, 20, 24, 28, 32, 36, 40
Query!
Secondary outcome [10]
0
0
Mean Changes From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Dyspnea
Query!
Assessment method [10]
0
0
Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. The Dyspnea sub-scale item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores indicate a higher level of symptoms; lower scores indicating lesser burden and improved symptoms or quality of life. A clinically meaningful change in score may be regarded as 10 points.
Query!
Timepoint [10]
0
0
Weeks 7, 16, 20, 24, 28, 32, 36, 40
Query!
Secondary outcome [11]
0
0
Mean Changes From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Insomnia
Query!
Assessment method [11]
0
0
Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. The Insomnia sub-scale item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores indicate a higher level of symptoms; lower scores indicating lesser burden and improved symptoms or quality of life. A clinically meaningful change in score may be regarded as 10 points.
Query!
Timepoint [11]
0
0
Weeks 7, 16, 20, 24, 28, 32, 36, 40
Query!
Secondary outcome [12]
0
0
Mean Changes From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Appetite Loss
Query!
Assessment method [12]
0
0
Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. The Appetite loss sub-scale item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores indicate a higher level of symptoms; lower scores indicating lesser burden and improved symptoms or quality of life. A clinically meaningful change in score may be regarded as 10 points.
Query!
Timepoint [12]
0
0
Weeks 7, 16, 20, 24, 28, 32, 36, 40
Query!
Secondary outcome [13]
0
0
Mean Changes From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Constipation
Query!
Assessment method [13]
0
0
Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. The Constipation sub-scale item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores indicate a higher level of symptoms; lower scores indicating lesser burden and improved symptoms or quality of life. A clinically meaningful change in score may be regarded as 10 points
Query!
Timepoint [13]
0
0
Weeks 7, 16, 20, 24, 28, 32, 36, 40
Query!
Secondary outcome [14]
0
0
Mean Changes From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Diarrhea
Query!
Assessment method [14]
0
0
Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. The Diarrhea sub-scale item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores indicate a higher level of symptoms; lower scores indicating lesser burden and improved symptoms or quality of life. A clinically meaningful change in score may be regarded as 10 points.
Query!
Timepoint [14]
0
0
Weeks 7, 16, 20, 24, 28, 32, 36, 40
Query!
Secondary outcome [15]
0
0
Mean Changes From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Financial Difficulties
Query!
Assessment method [15]
0
0
Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. The Financial difficulties sub-scale item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores indicate a higher level of symptoms; lower scores indicating lesser burden and improved symptoms or quality of life. A clinically meaningful change in score may be regarded as 10 points
Query!
Timepoint [15]
0
0
Weeks 7, 16, 20, 24, 28, 32, 36, 40
Query!
Secondary outcome [16]
0
0
Mean Changes From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Fatigue
Query!
Assessment method [16]
0
0
Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. The Fatigue sub-scale item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores indicate a higher level of symptoms; lower scores indicating lesser burden and improved symptoms or quality of life. A clinically meaningful change in score may be regarded as 10 points
Query!
Timepoint [16]
0
0
Weeks 7, 16, 20, 24, 28, 32, 36, 40
Query!
Secondary outcome [17]
0
0
Mean Changes From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Nausea and Vomiting
Query!
Assessment method [17]
0
0
Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. The Nausea and Vomiting sub-scale item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores indicate a higher level of symptoms; lower scores indicating lesser burden and improved symptoms or quality of life. A clinically meaningful change in score may be regarded as 10 points for the various scales of the EORTC QLQ-C30
Query!
Timepoint [17]
0
0
Weeks 7, 16, 20, 24, 28, 32, 36, 40
Query!
Secondary outcome [18]
0
0
Mean Changes From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Pain
Query!
Assessment method [18]
0
0
Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. The Pain sub-scale item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores indicate a higher level of symptoms; lower scores indicating lesser burden and improved symptoms or quality of life. A clinically meaningful change in score may be regarded as 10 points
Query!
Timepoint [18]
0
0
Weeks 7, 16, 20, 24, 28, 32, 36, 40
Query!
Eligibility
Key inclusion criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
- Subject must have been diagnosed with stage III or/and stage IV histologically
confirmed melanoma [per American Joint Committee on Cancer (AJCC) staging system] that
is unresectable or metastatic
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Subject has not been treated by systemic anticancer therapy for unresectable or
metastatic melanoma
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subjects with active brain metastases or leptomeningeal metastases
- Subjects with ocular melanoma
- Subjects with active, known or suspected autoimmune disease
Other protocol defined inclusion/exclusion criteria could apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
4/04/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
28/05/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
387
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Local Institution - North Sydney
Query!
Recruitment hospital [2]
0
0
Local Institution - 0045 - Waratah
Query!
Recruitment hospital [3]
0
0
Local Institution - Greenslopes
Query!
Recruitment hospital [4]
0
0
Local Institution - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2060 - North Sydney
Query!
Recruitment postcode(s) [2]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [3]
0
0
4120 - Greenslopes
Query!
Recruitment postcode(s) [4]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Colorado
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Minnesota
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Missouri
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Nevada
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New Hampshire
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New Jersey
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
North Carolina
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Pennsylvania
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Virginia
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Washington
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
Alberta
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
Ontario
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Quebec
Query!
Country [15]
0
0
Denmark
Query!
State/province [15]
0
0
Aarhus N
Query!
Country [16]
0
0
Denmark
Query!
State/province [16]
0
0
Herlev
Query!
Country [17]
0
0
Denmark
Query!
State/province [17]
0
0
Odense
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Bordeaux
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Lille
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Marseille Cedex 5
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Nantes Cedex
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Paris
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Pierre Benite
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Toulouse Cedex 9
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Villejuif
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Essen
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Heidelberg
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Muenchen
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Tuebingen
Query!
Country [30]
0
0
Israel
Query!
State/province [30]
0
0
Ramat Gan
Query!
Country [31]
0
0
Italy
Query!
State/province [31]
0
0
Bergamo
Query!
Country [32]
0
0
Italy
Query!
State/province [32]
0
0
Milano
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
Napoli
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
Padova
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Siena
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Taormina
Query!
Country [37]
0
0
Netherlands
Query!
State/province [37]
0
0
Amsterdam
Query!
Country [38]
0
0
Netherlands
Query!
State/province [38]
0
0
Groningen
Query!
Country [39]
0
0
Poland
Query!
State/province [39]
0
0
Gdansk
Query!
Country [40]
0
0
Poland
Query!
State/province [40]
0
0
Krakow
Query!
Country [41]
0
0
Poland
Query!
State/province [41]
0
0
Warszawa
Query!
Country [42]
0
0
Russian Federation
Query!
State/province [42]
0
0
Moscow
Query!
Country [43]
0
0
Spain
Query!
State/province [43]
0
0
Badalona-barcelona
Query!
Country [44]
0
0
Spain
Query!
State/province [44]
0
0
Barcelona
Query!
Country [45]
0
0
Spain
Query!
State/province [45]
0
0
Madrid
Query!
Country [46]
0
0
Spain
Query!
State/province [46]
0
0
San Sabastian Gipuzkoa
Query!
Country [47]
0
0
Spain
Query!
State/province [47]
0
0
Valencia
Query!
Country [48]
0
0
United Kingdom
Query!
State/province [48]
0
0
Greater Manchester
Query!
Country [49]
0
0
United Kingdom
Query!
State/province [49]
0
0
Oxfordshire
Query!
Country [50]
0
0
United Kingdom
Query!
State/province [50]
0
0
Guildford
Query!
Country [51]
0
0
United Kingdom
Query!
State/province [51]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate two different dose combinations of nivolumab and
ipilimumab in the treatment of melanoma.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02714218
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02714218
Download to PDF